Sched.com Conference Mobile Apps
bwge2020 has ended
Create Your Own Event
bwge2020
-
Saved To
My Schedule
Schedule
Simple
Expanded
Grid
By Venue
Speakers
Attendees
Search
or browse by date + venue
BASL / BLIC
All
Session 1
Session 2
Session 3
Session 4
BeSPGHAN
BGDO
All
Session 1
Session 2
BIRD
All
Session 1 IBD Basic
Session 2 IBD Basic
BIRD/BeSPGHAN
All
Session 3 IBD Clinic/BeSPGHAN
Session 4 IBD Clinic/BeSPGHAN
BPC
All
Session 1
Session 2
BROHEE
BSGIE
All
Session 1
Session 2
Session 3
e-Posters Tour
BSGIE Live
All
Session 1
Session 2
Case Reports GE
All
Session 1
Session 2
Case Reports Hepathology
All
Session 1
Session 2
GIREM
All
Session 1
Session 2
Session 3
Session 4
Oral Top Posters - Short talks
All
Basic
PG Course
All
Afternoon Session
Morning Session
Proctology
All
Session 1
Session 2
Ultrasound Course
WGD Pathology
All
Session 1
Session 2
Young BASL
All
Session 1
Session 2
Popular
Sign up
or
log in
to bookmark your favorites and sync them to your phone or calendar.
menu
Menu
Schedule
Speakers
Attendees
Search
tune
Filter sessions
Simple
Expanded
Grid
By Venue
Wednesday
, March 4
Exhibition Area
10:10 •
Coffee Break
12:20 •
Lunch
15:25 •
Coffee Break
15:30 •
Coffee Break
16:00 •
Coffee Break
Room SANCY
14:00 •
Different approaches to Hepato-Cellular Carcinoma diagnosis: from the molecular to the radiological perspective. Molecular Perspective
14:45 •
Different approaches to Hepato-Cellular Carcinoma diagnosis: from the molecular to the radiological perspective. Radiologist Perspective
16:00 •
MSD Best Clinical and Basic Publications 2019: Glycome Patterns of Perfusate in Livers Before Transplantation Associate With Primary Nonfunction.
16:20 •
Combination of Gene Expression Signature and Model for End-Stage Liver Disease Score Predicts Survival of Patients With Severe Alcoholic Hepatitis.
16:40 •
Invited Talk - Starter Investigators: Contribution of gEnome-wide eXPression profiLes tO the Risk of hEpatocellular carcinoma (EXPLORE)
16:55 •
Therapeutic potential of isoform-specific HIF-1α and HIF-2α antisense oligonucleotides in a hepatocellular carcinoma mouse model
17:10 •
Intestinal mucosal immunity in the pathogenesis of primary sclerosing cholangitis
Room TEUN + LIJN
08:30 •
Management of acute alcoholic hepatitis
08:55 •
Treatment algorithm for hepatocellular carcinoma
09:20 •
How to manage pancreatic cysts? When are they benign?
09:45 •
Early diagnosis of pancreatic cancer
10:40 •
Clinical management in chronic diarrhea
11:05 •
Prevention of infections in IBD
11:30 •
Management of dysplasia in IBD
11:55 •
Metastasized colorectal cancer: therapeutic strategies
13:45 •
Achalasia. What is the ideal long-term treatment?
14:10 •
Therapy refractory reflux: what to do if PPI’s fail?
14:35 •
Helicobacter pylori in 2020… Still an issue?
15:00 •
Constipation: a practical approach
16:00 •
Duodenal polyps: identification and management strategy
16:25 •
Lower gastro-intestinal bleeding
16:50 •
Endoscopic polypectomy: hot or cold?
Room TIFFANY-SHAH
14:00 •
Genes involved in gut homeostasis: focus on enteroctyes
14:25 •
Integrin expression changes on the T cell subsets influence the response to vedolizumab in inflammatory bowel disease patients
14:35 •
The interplay of microbiome dysbiosis and immune system deregulation in patients with Crohn’s disease
14:45 •
Exposure to an inflammatory mix re-induces inflammation in organoids of ulcerative colitis patients, independent of the inflammatory state of the tissue of origin
14:55 •
Serum protein markers for early and differential IBD diagnosis validated by machine learning approaches
15:05 •
Early inflammatory and monogenic diseases (title to confirm)
15:30 •
Coffee Break Symposium TAKEDA
16:15 •
A mucosal marker predicting tofacitinib induced endoscopic response in ulcerative colitis
16:25 •
SLC12A2 as a potential histological marker of ulcerative colitis associated colorectal dysplasia
16:35 •
The gut microbiota during biological therapy for inflammatory bowel disease.
16:45 •
Role of exosomal microRNAs in fibrotic disease
17:10 •
Satellite Symposium PFIZER
TBA
17:00 •
Ultrasound Hands-on Course
Thursday
, March 5
e-Posters Area
13:00 •
BSGIE e-Posters Session
ePoster Area
12:00 •
Oral Top Basic e-Posters
Exhibition Area
10:30 •
Coffee Break
10:55 •
Coffee Break
12:30 •
Lunch
15:00 •
Coffee Break
15:30 •
Coffee Break
Exposition Area
10:15 •
Coffee Break
10:30 •
Coffee Break
12:35 •
Lunch
15:20 •
Coffee Break
15:30 •
Coffee Break
Room LIJN
14:00 •
WIDE AREA TRANSEPITHELIAL SAMPLE ESOPHAGEAL BIOPSY COMBINED WITH COMPUTER ASSISTED 3-DIMENSIONAL TISSUE ANALYSIS (WATS3D) FOR THE DETECTION OF HIGH GRADE DYSPLASIA AND ADENOCARCINOMA IN BARRETT: EUROPEAN MULTI-CENTER, PROSPECTIVE, RANDOMIZED, TANDEM STUDY
14:12 •
A prospective, multi-center validation study for automated polyp detection as a second observer.
14:24 •
The incremental benefit of dye-based chromoendoscopy as compared to high-definition white light and virtual chromoendoscopy for lesion assessment and prediction of SMI.
14:36 •
Mucosal capillary pattern recognition based on automated image analysis during endoscopy accurately detects histological remission in ulcerative colitis.
14:48 •
Continuous ADR50 monitoring with individual feedback in lower gastrointestinal endoscopy, a quality improvement initiative in a Brussels public hospital.
15:00 •
Management of common bile duct stones
16:00 •
Thermal ablation of the mucosal defect margin after endoscopic mucosal resection significantly reduces adenoma recurrence – A prospective, international, multi-centre trial.
16:12 •
EUS-guided intrahepatic access for retrograde, antegrade or transgastric biliary drainage: indications, efficacy and safety from an 8-year tertiary centre experience.
16:24 •
Electrocautery-enhanced lumen-apposing metal stents for approved and non-approved indications: a 2-year single-centre experience.
16:36 •
Covert carcinoma among rectal ESD specimen is high: a European tertiary center prospectively collected experience.
16:36 •
Superficial adenocarcinoma of the esophagogastric junction (AEGJ) : outcomes of ESD in a Western cohort.
16:50 •
Endoscopic management of chronic pancreatitis
17:20 •
BSGIE Award Ceremony (Best Presentation / Best Abstract)
Room SANCY
09:00 •
A curious case of collagenous colitis
09:15 •
Intestinal spirochetosis : Think about it to diagnose it.
09:30 •
An ileal GIST as a rare cause of overt lower gastro-intestinal bleeding in a 25-year old woman: a case report.
09:45 •
Pseudo-achalasia secondary to oesophageal deviation resulting from mediastinal shift and right atrial enlargement after left lower lobectomy.
10:00 •
A PET-positive nodule after chemotherapy
10:45 •
Neoadjuvant immunotherapy for a MSI-H locally advanced rectal cancer patient: should we define new standard of care for these patients?
11:00 •
Spontaneous Pneumobilia
11:15 •
Not probiotic-related Saccharomyces cerevisiae fungemia in an intensive care patient, a case report
11:30 •
A case of miliary abdominal tuberculosis in an anti-TNF treated patient with Crohn’s disease
11:45 •
Mantle cell lymphoma simulating inflammatory bowel disease
13:00 •
BeSPGHAN General Assembly
14:00 •
Post induction infliximab trough levels predict long-term endoscopic remission in paediatric patients with Inflammatory Bowel Disease.
14:15 •
Detection of Helicobacter pylori in children and adolescents: diagnosis and treatment in Jessa Hospital between 2016 and 2019.
14:30 •
Achalasia or pseudo-achalasia in a 2-year-old boy
14:45 •
Use of Ustikinumab in an infant with very early onset inflammatory bowel disease: 18 months follow-up
15:30 •
On Boarding Improved Care Now for participating centers.
Room TEUN
08:00 •
Breakfast Symposium EISAI/MSD
08:30 •
Safety and preliminary efficacy of human adult liver progenitor cells (HepaStem™) in patients with acute-on-chronic liver failure (ACLF) or acute decompensation (AD) at risk of developing ACLF
08:40 •
Viral hepatitis in Belgian prisons: a first-time multicenter prevalence study
08:50 •
Hypoxia-induced angiogenesis protects the liver from small for size syndrome
09:00 •
Is there a room for a specific diet approach in IBD? (title to confirm)
09:00 •
18F-Fluorocholine and 18F-Fluorodesoxyglucose PET/CT for Clinical Staging of patients with Hepatocellular Carcinoma
09:10 •
Are liver inclusive intestinal grafts protected against rejection?
09:20 •
Prevalence and characteristics of cystic fibrosis-associated liver disease in a cohort of adult cystic fibrosis patients
09:25 •
Development and validation of dried blood spot sampling as a tool to identify the best time point to measure predictive ustekinumab serum concentrations in patients with Crohn’s disease
09:30 •
Brohee Lecture - NASH, think outside the liver
09:35 •
Safety of the sequential use of biological therapy in inflammatory bowel disease: results from a tertiary referral centre.
09:45 •
Neoplastic lesions outside diseased area in IBD patients: A National Cohort Study
09:55 •
PROSPECTIVE STUDY OF PHARMACOKINETICS OF INFLIXIMAB DURING INDUCTION IN PATIENTS WITH CROHN’S DISEASE AND ULCERATIVE COLITIS (PACIFIC)
10:00 •
Coffee Break Symposium BAYER
10:05 •
How switching to biosimilar infliximab led to stopping treatment in 3 pediatric Crohn patients
10:15 •
Impact of genetic burden on familial aggregation of inflammatory bowel disease
10:25 •
Coffee Break Symposium BIOGEN
10:45 •
Pitfalls of bariatric surgery in NAFLD and liver transplant patients
11:10 •
How can telemedicine and patient empowerment improve IBD care in 2020? (title to confirm)
11:15 •
Plasma protein glycomics combined with circulating fragments of cytokeratin-18 are reliable biomarkers to diagnose alcoholic hepatitis
11:26 •
Long-term outcome of symptomatic alcoholic hepatitis with a Maddrey discriminant function < 32.
11:35 •
Vedolizumab concentrations in colonic mucosal tissue of ulcerative colitis patients inversely correlate with the severity of inflammation
11:37 •
The link between the gut and the liver during early alcoholic liver disease
11:45 •
Safety and efficacy of combining biological therapies together or with small molecules in patients with Inflammatory Bowel Disease: a retrospective multicenter national observational case series study.
11:48 •
Role of the gut microbiota in the modulation of the gut-liver-brain axis in alcohol use disorders: proof of concept with the fecal microbiota transplantation
11:55 •
Tofacitinib induces clinical and endoscopic remission in biologic refractory Ulcerative Colitis patients: A real-world Belgian cohort study
11:59 •
Myosteatosis is associated with early NASH in the context of obesity and metabolic syndrome
12:05 •
How to do a tight monitoring in Crohn’s disease: role of small bowel capsule endoscopy, entero-MRI and other morphologic explorations (title to confirm)
12:10 •
Hepatitis E Virus Genotype 3 subtype dependent clinical outcomes in Belgium 2010 – 2018
12:21 •
Transcriptome profiling of liver biopsies before antiviral treatment start can predict HCC development 8.3 years before clinical diagnosis in chronic Hepatitis B and C patients
12:30 •
Satellite Symposium JANSSEN
13:15 •
Satellite Symposium GILEAD
14:00 •
Unlike HbA1c level and the amount of visceral adipose tissue, the presence and severity of NAFLD do not predict the occurrence of major adverse cardiovascular events in an obese Belgian population
14:10 •
Do patients with NAFLD have an increased incidence of cardiovascular complications after liver transplantation?
14:20 •
Alcoholic liver disease and liver transplantation in patients with prior bariatric surgery
14:30 •
Efficacy of enteroscopy-assisted ERCP in liver transplant patients with Roux-en-Y reconstruction and suspected bile duct pathology.
14:40 •
Prediction of mortality in cirrhotic patients before surgery
15:40 •
Myeloid IRE1a deletion alters hepatic macrophage phenotype and attenuates experimental non-alcoholic steatohepatitis-related hepatocellular carcinoma
15:50 •
Active Non-alcoholic steatohepatitis and severe fibrosis are associated with dysfunctional adipose tissue and worsen with more severe adipose tissue insulin resistance independently of Body mass index
16:00 •
Muscle fat infiltration in obese patients is associated with NAFLD related fibrosis severity – results from a prospective body composition and imaging study
16:10 •
The mechanisms of steatosis pathogenesis during NASH development
16:20 •
Neutralizing anti-CD8 antibodies effectively reduce visceral adipose tissue cytotoxic T cells and attenuate NAFLD in a high-fat high-fructose diet mouse model
16:30 •
Case-finding of Non-alcoholic fatty liver disease-induced liver fibrosis: prevalence and use of non-invasive scoring vs. transient elastography in primary care
16:40 •
The effects of oral bosentan treatment on the increased intrahepatic vascular resistance and disease severity of early NAFLD in rats
16:50 •
Impact of amino acid supplementation on sarcopenia in NASH
17:00 •
Assessment of liver fibrosis stage in active NASH by VCT
17:15 •
Satellite Symposium ALNYLAM
17:45 •
BASL Prizes & General Assembly
Room TIFFANY/SHAH
09:00 •
Characterizing the development of coordinated activity in the human fetal gut neuromusculature.
09:45 •
Human and bacterial-derived amyloids trigger a distinct transcriptional response in primary myenteric networks.
10:00 •
Sex-difference in the gastrointestinal phenotype depends on the susceptibility for co-morbid disorders such as anxiety.
10:15 •
Examining the processing of luminal information by the Enteric Nervous System using Ca2+ imaging.
11:00 •
The contribution of sodium channels to sensory Perception in the gut.
11:45 •
Beneficial effects of the locally administered TRPV4-antagonist HC-067047 in a post-inflammatory rat model for visceral hypersensitivity.
12:00 •
Duodenal bile salts and mucosal changes are linked with gastric emptying and symptoms in functional dyspepsia patients.
12:15 •
Inhibition of adhesiogenesis with protease inhibitors Nafamostat Mesylate, UAMC-00050, and Enoxaparin in a murine model for sepsis and peritonitis.
13:30 •
The gut-liver axis in health and disease – prospects of understanding and targeting macrophages.
14:15 •
Crosstalk between monocyte-derived macrophages and enteric glial cell Is essential for tissue repair and recovery of gastrointestinal transit after intestinal inflammation.
14:30 •
Role of bitter taste receptors on innate immunity in jejunal crypts from lean and obese subjects.
14:45 •
Anti-inflammatory effects on duodenal eosinophilia rather than acid-suppressive effects explain therapeutic efficacy of proton pump inhibitors in functional dyspepsia patients.
15:00 •
Innate immune cell populations characterise the disrupted gut-liver axis in Experimental PSC-UC.
15:15 •
Economic burden in primary care irritable bowel syndrome patients with different stool pattern subtypes.
16:00 •
Exploring the molecular signalling pathways of MUC1 and MUC13 in intestinal epithelial cells during inflammation in vitro: important Mediators of intestinal barrier integrity?
16:15 •
Postinfectious onset in functional dyspepsia is a risk factor for weight loss.
16:30 •
Volatile organic compound profiling of breath samples as a biomarker to discriminate between patients with irritable bowel syndrome and healthy controls: a feasibility study.
16:45 •
Predictors of treatment response to the traditional and the low FODMAP diet for patients with irritable bowel syndrome.
17:00 •
Somatization, anxiety, depression and fear of pain levels are not significantly different across the gastroesophageal reflux disease spectrum.
Friday
, March 6
Exhibition Area
10:00 •
Coffee Break
10:15 •
Coffee Break
10:30 •
Coffee Break
10:30 •
Coffee Break
12:30 •
Lunch
15:30 •
Coffee Break
Exposition Area
15:00 •
Coffee Break
Room LIJN
09:00 •
Oesophagitis (non-Barrett).
09:30 •
Dysplasia and submucosal oesophageal lesions: what gastroenterologists want to know from pathologists?
10:30 •
Pathology of Barrett’s oesophagus: from metaplasia to dysplasia and cancer.
11:15 •
Low-grade dysplasia in Barrett’s esophagus is downgraded in half of the cases after systematic expert pathology review before patient referral for endoscopic treatment.
11:30 •
Subacute liver failure in a pregnant female.
11:45 •
Actinomycosis of the pancreas: a case report.
12:00 •
An unusual appendiceal mass rises a diagnostic challenge.
12:15 •
Gastritis: demographic and environmental factors based on a cross-sectional study in Belgium and Bukavu.
13:30 •
Standardized macroscopic examination for cancer of the oesophagus and oesophagogastric junction.
14:00 •
Diagnostic criteria and histopathological reporting of malignant epithelial oesophageal tumours.
14:30 •
Molecular pathology of oesophageal cancer and its clinical implications.
15:30 •
Diagnosing Strongyloides in biopsy specimens: a case report.
15:45 •
81-year-old man with ulcerated mass in the caecum.
16:00 •
Incidence of appendiceal NEN and adherence to pathology classification rules in Belgium.
16:15 •
Incidence of rectal NEN and adherence to pathology classification rules in Belgium.
Room TEUN
08:30 •
Breakfast Symposium ELI LILLY
09:00 •
Real world incidence of microsatellite instability or EBV positivity in a Belgian cohort of patients with adenocarcinoma of the esophagus, gastroesophageal junction and stomach
09:15 •
Induction by mFOLFIRINOX followed by stereotaxic body radiotherapy with simultaneous integrated boost (SIB-SBRT) at the tumor-vessel interfaces (TVI) for the neoadjuvant treatment of localized pancreatic cancers.
09:30 •
Feasibility and clinical impact of routine molecular testing of gastrointestinal (GI) cancers at a tertiary centre with a multi-gene, next generation sequencing (NGS) panel
09:45 •
DNA Methylation Analysis of the PDX1 Gene can be used for PNET Subtyping and has a Possible Prognostic Value
10:00 •
FIGHT-202: A phase 2 study of pemigatinib in patients with previously treated locally advanced or metastatic cholangiocarcinoma
10:15 •
“NEOPAC”: A multi-centric prospective observational registry on the NEOadjuvant therapeutic approach to the localised PAncreatiC adenocarcimona, a collaborative multicentric project (CHU Liège – FLCD - CUSL – ULB Erasme).
11:00 •
Upper GI cancers.
11:00 •
Highlights of the Year
11:20 •
Hepato-Bilio-Pancreatic cancers.
11:40 •
Colo-Rectal cancers.
12:00 •
DPD-flash & BGDO Award
14:00 •
Anatomic variations of the bilio-pancreatic ductal system and bilio-pancreatic diseases.
14:30 •
Feasibility and safety of EUS-guided placement of fiducial markers for stereotactic body radiation therapy in pancreatic cancer: a prospective evaluation.
14:45 •
Long-term safety of indwelling double pigtail stents for drainage of pancreatic collections with disconnected pancreatic duct syndrome.
15:00 •
Endoscopic ultrasounded-guided radiofrequency ablation for pancreatic lesions: Belgian experience.
15:15 •
Treatment of a large WON with a novel instrument: the EndoRotor DEN Microdebrider.
16:00 •
New ESGE update on PEP prevention guidelines.
16:30 •
Autoimmune pancreatitis: beware of malignancies.
16:40 •
Groove Pancreatitis.
16:50 •
Nivolumab-induced pancreatitis.
17:00 •
Opioid related sphincter of Oddi dysfunction causing double duct sign in a patient with gastric bypass.
Room TIFFANY-SHAH
09:00 •
Case presentation by BygGIE (Belgian young group of GI Endoscopists)
09:00 •
Live Demonstrations
09:00 •
Brief talk (between cases) complication management in ERCP/EUS
11:00 •
Case presentation by BygGIE (Belgian young group of GI Endoscopists)
11:00 •
Live Demonstrations
Room TIFFANY/SHAH
14:00 •
Injection of botulinum toxin significantly increases efficiency of fissurectomy in the treatment of chronic anal fissures
14:00 •
Hemorrhoidal disease and selected abstracts
14:10 •
Anal dysplasia in HIV-seropositive men. Prevalence in the Ghent population.
14:20 •
Postgraduate symposium. Hemorrhoidal disease.
15:00 •
What is symptomatic hemorrhoidal disease?
15:15 •
Critical appraisal of (new) interventional techniques in hemorrhoidal disease.
15:30 •
Summary of the Belgian guidelines in hemorrhoidal disease: conservative treatment.
16:00 •
Summary of the Belgian guidelines in hemorrhoidal disease: surgical treatment.
16:30 •
The Belgian Week Proctology Quiz.
TBA
09:00 •
Biliary complications in human alveolar echinococcosis: a case report.
09:15 •
Just another liver cyst (or not!)
09:30 •
Pleural effusion and elevated liver tests: think viral!
09:45 •
Bile duct stone extraction via PTC rendezvous assisted single balloon ERCP.
10:00 •
Acute grade IV toxic hepatitis due to the e-sigarette.
10:45 •
Resolution of a Hepatoduodenal fistula after nivolumab treatment in a patient with advanced hepatocellular carcinoma: challenges in immunotherapy.
11:00 •
A rare complication of Lemmel Syndrome: Biliary-Diverticular Fistula from a Duodenal Diverticulum
11:15 •
Dubai took my breath away
11:30 •
Reopening of the native portomesenteric axis after cavoportal hemitransposition in a liver transplant patient
11:45 •
The use of ribavirin in a severe case of hepatitis E infection necessitating renal replacement therapy.
Timezone
bwge2020
Europe/Brussels
Filter By Date
bwge2020
Mar 4
-
6, 2020
Wednesday
, March 4
Thursday
, March 5
Friday
, March 6
Filter By Venue
Venues
Sort schedule by Venue
e-Posters Area
ePoster Area
Exhibition Area
Exposition Area
Room LIJN
Room SANCY
Room TEUN
Room TEUN + LIJN
Room TIFFANY-SHAH
Room TIFFANY/SHAH
TBA
Filter By Type
BASL / BLIC
All
Session 1
Session 2
Session 3
Session 4
BeSPGHAN
BGDO
All
Session 1
Session 2
BIRD
All
Session 1 IBD Basic
Session 2 IBD Basic
BIRD/BeSPGHAN
All
Session 3 IBD Clinic/BeSPGHAN
Session 4 IBD Clinic/BeSPGHAN
BPC
All
Session 1
Session 2
BROHEE
BSGIE
All
Session 1
Session 2
Session 3
e-Posters Tour
BSGIE Live
All
Session 1
Session 2
Case Reports GE
All
Session 1
Session 2
Case Reports Hepathology
All
Session 1
Session 2
GIREM
All
Session 1
Session 2
Session 3
Session 4
Oral Top Posters - Short talks
All
Basic
PG Course
All
Afternoon Session
Morning Session
Proctology
All
Session 1
Session 2
Ultrasound Course
WGD Pathology
All
Session 1
Session 2
Young BASL
All
Session 1
Session 2
Popular
Recently Active Attendees
J
Josephmug
G
grihin
Y
you_cash
O
orangecarphuket.com
J
Josezins
PV
PEDRO VILLASANA
V
vnwailian
G
gotutop
More →
Filter sessions
Apply filters to sessions.
close
Dates
Wednesday
, March 4
Thursday
, March 5
Friday
, March 6
Venue
e-Posters Area
ePoster Area
Exhibition Area
Exposition Area
Room LIJN
Room SANCY
Room TEUN
Room TEUN + LIJN
Room TIFFANY-SHAH
Room TIFFANY/SHAH
TBA
Session Type
BASL / BLIC
All
Session 1
Session 2
Session 3
Session 4
BeSPGHAN
BGDO
All
Session 1
Session 2
BIRD
All
Session 1 IBD Basic
Session 2 IBD Basic
BIRD/BeSPGHAN
All
Session 3 IBD Clinic/BeSPGHAN
Session 4 IBD Clinic/BeSPGHAN
BPC
All
Session 1
Session 2
BROHEE
BSGIE
All
Session 1
Session 2
Session 3
e-Posters Tour
BSGIE Live
All
Session 1
Session 2
Case Reports GE
All
Session 1
Session 2
Case Reports Hepathology
All
Session 1
Session 2
GIREM
All
Session 1
Session 2
Session 3
Session 4
Oral Top Posters - Short talks
All
Basic
PG Course
All
Afternoon Session
Morning Session
Proctology
All
Session 1
Session 2
Ultrasound Course
WGD Pathology
All
Session 1
Session 2
Young BASL
All
Session 1
Session 2
Other Filters
Popular
